- $2.74bn
- $3.07bn
- $2.51bn
- 57
- 67
- 68
- 69
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 15.3 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.94 | ||
| Price to Tang. Book | 119.33 | ||
| Price to Free Cashflow | 9.07 | ||
| Price to Sales | 1.09 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -23.22% | ||
| Return on Equity | -31.47% | ||
| Operating Margin | -41.35% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1,929.1 | 2,508.9 | 2,569.1 | 2,566.5 | 2,510.6 | 2,517.37 | 2,596 | 1.9% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -50.45 | +160.99 | -15.63 | -64.79 | n/a | n/a | +15.09 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Envista Holdings Corporation is a global dental products company. The Company's diversified portfolio of solutions covers a range of dentists' clinical needs for preventing, diagnosing, and treating dental conditions as well as improving the aesthetics of the human smile. It has more than 30 dental brands, including Nobel Biocare, Ormco, DEXIS and Kerr. Its segments include Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment primarily develops, manufactures and markets dental implant systems, including regenerative solutions, dental prosthetics and associated treatment software and technologies, as well as orthodontic bracket systems, aligners and lab products. The Equipment & Consumables segment primarily develops, manufactures, and markets dental equipment and supplies used in dental offices, including digital imaging systems, software, and other visualization/magnification systems; and endodontic systems and related products.
Directors
- Scott Huennekens NEC (56)
- Amir Aghdaei PRE (63)
- Howard Yu CFO (49)
- Curt Bludworth CHO (54)
- Mark Nance SVP (53)
- Patrik Eriksson SVP (53)
- Jeffrey Kappler SVP (42)
- Jean-Claude Kyrillos SVP (57)
- Mischa Reis SVP (49)
- Daniel Raskas DRC (54)
- Wendy Carruthers IND (52)
- Kieran Gallahue IND (57)
- Barbara Hulit IND (54)
- Vivek Jain IND (61)
- Christine Tsingos IND (63)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- August 29th, 2018
- Public Since
- September 18th, 2019
- No. of Shareholders
- 18
- No. of Employees
- 12,300
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
New York Stock Exchange- Shares in Issue
- 172,188,060
- Address
- 200 S. Kraemer Blvd., Bldg. E, BREA, 92821
- Web
- https://envistaco.com/en
- Phone
- +1 7148175418
- Auditors
- Ernst & Young LLP
Latest News for NVST
Upcoming Events for NVST
Q1 2025 Envista Holdings Corp Earnings Release
Q1 2025 Envista Holdings Corp Earnings Call
Envista Holdings Corp Annual Shareholders Meeting
Envista Holdings Corp Annual Shareholders Meeting
Q2 2025 Envista Holdings Corp Earnings Release
Similar to NVST
Abbott Laboratories
New York Stock Exchange
Agilent Technologies
New York Stock Exchange
Alcon AG
New York Stock Exchange
Artivion
New York Stock Exchange
Avanos Medical
New York Stock Exchange
FAQ
As of Today at 20:28 UTC, shares in Envista Holdings are trading at $15.94. This share price information is delayed by 15 minutes.
Shares in Envista Holdings last closed at $15.94 and the price had moved by -20.38% over the past 365 days. In terms of relative price strength the Envista Holdings share price has underperformed the S&P500 Index by -26.51% over the past year.
The overall consensus recommendation for Envista Holdings is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreEnvista Holdings does not currently pay a dividend.
Envista Holdings does not currently pay a dividend.
Envista Holdings does not currently pay a dividend.
To buy shares in Envista Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $15.94, shares in Envista Holdings had a market capitalisation of $2.74bn.
Here are the trading details for Envista Holdings:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: NVST
Based on an overall assessment of its quality, value and momentum Envista Holdings is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Envista Holdings is $20.36. That is 27.73% above the last closing price of $15.94.
Analysts covering Envista Holdings currently have a consensus Earnings Per Share (EPS) forecast of $0.99 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Envista Holdings. Over the past six months, its share price has underperformed the S&P500 Index by -11.06%.
As of the last closing price of $15.94, shares in Envista Holdings were trading -14.56% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Envista Holdings PE ratio based on its reported earnings over the past 12 months is 15.3. The shares last closed at $15.94.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Envista Holdings' management team is headed by:
- Scott Huennekens - NEC
- Amir Aghdaei - PRE
- Howard Yu - CFO
- Curt Bludworth - CHO
- Mark Nance - SVP
- Patrik Eriksson - SVP
- Jeffrey Kappler - SVP
- Jean-Claude Kyrillos - SVP
- Mischa Reis - SVP
- Daniel Raskas - DRC
- Wendy Carruthers - IND
- Kieran Gallahue - IND
- Barbara Hulit - IND
- Vivek Jain - IND
- Christine Tsingos - IND